



# Arkansas Department of Health

4815 West Markham Street • Little Rock, Arkansas 72205-3867 • Telephone (501) 661-2000  
Governor Asa Hutchinson  
José R. Romero, MD, Secretary of Health

## **SUMMARY OF PROPOSED AMENDMENTS TO RULES PERTAINING TO THE LIST OF CONTROLLED SUBSTANCES FOR THE STATE OF ARKANSAS**

The proposed listed amendments update List of Controlled Substances to include these drugs.

1. Acetyl fentanyl, Valeryl fentanyl, Isobutyryl fentanyl, 4-methoxy butyryl fentanyl and Acetyl norfentanyl are opiates listed as Schedule I controlled substances. Page 2, (b), (59), (60), (62), (64) and (66). These items are marked for clean up. The salt designation is removed from the chemical nomenclature for these substances. References to salt formulations is currently documented in prefatory language for opiates in Schedule I. Page 2, (b), (59), (60), (62), (64) and (66).
2. Para-fluorobutyryl fentanyl is a Schedule 1 controlled substance. To follow DEA, a DEA Controlled Substance Code Number has been set forth opposite of this substance and is marked for clean up. The salt designation has also been removed from the chemical nomenclature for this substance as references to salt formulation is documented in the prefatory language for opiates in Schedule I Page 2, (b), (65)
3. Cyclopropyl fentanyl. N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. To follow DEA scheduling, this drug would be included as Schedule I. Page 3, (b), (75).
4. Methoxyacetyl fentanyl. 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. To follow DEA scheduling, this drug would be included as Schedule I. Page 3, (b), (76).
5. Ortho-fluorofentanyl. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide). The DEA has placed this opioid analgesic into schedule I because it has no recognized medical use. To follow DEA

scheduling, this drug would be included as Schedule I. Page 3, (b) (77).

6. Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substances means any substance not otherwise listed, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:

(A) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

(B) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;

(C) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;

(D) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or

(E) Replacement of the *N*-propionyl group by another acyl group.

Felisia Lackey, Chief Forensic Chemist-Drug Section, Arkansas State Crime Laboratory, requested this substance designation for fentanyl related substances with one or more of the following modifications and without a recognized medical use be included into Schedule I. Page 3, (b), (78).

7. Clonazepam. Felisia Lackey, Chief Forensic Chemist-Drug Section, Arkansas State Crime Laboratory, requested that this depressant substance with no recognized medical use be included into Schedule I. Page 6, (e), (6).
8. Flualprazolam. Felisia Lackey, Chief Forensic Chemist-Drug Section, Arkansas State Crime Laboratory, requested that this depressant substance with no recognized medical use be included into Schedule I. Page 6, (e), (7).
9. Flubromazepam. Felisia Lackey, Chief Forensic Chemist-Drug Section, Arkansas State Crime Laboratory, requested that this depressant substance with no recognized medical use be included into Schedule I. Page 6, (e), (8).

10. Flubromazolam. Felisia Lackey, Chief Forensic Chemist-Drug Section, Arkansas State Crime Laboratory, requested that this depressant substance with no recognized medical use be included into Schedule I. Page 6, (e), (9).
11. Ethylone. 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one. The DEA has placed this synthetic cathinone into Schedule I because it has no recognized medical use. To follow DEA scheduling, this drug would be included as Schedule I. Page 7, (11), (b), (19).
12. Eutylone. 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone. Felisia Lackey, Chief Forensic Chemist-drug Section, Arkansas State Crime Laboratory, requested this synthetic cathinone with no recognized medical use be included into Schedule I. Page 7, (11), (b), (20).
13. Noroxymorphone. The DEA placed this opioid analgesic into Schedule II. To follow DEA scheduling, this substance would be included as Schedule II. Page 8, (b), (1), (20).
14. Thiafentanil. The DEA placed this opioid analgesic into Schedule II. To follow DEA scheduling, this substance would be included as Schedule II. Page 9, (c), (28).
15. Norfentanyl. N-phenyl-N-(piperidin-4-yl)propionamide. The DEA has placed this immediate precursor to fentanyl into Schedule II. To follow DEA scheduling, this substance would be included as Schedule II. Page 10, (g), (3), (ii).
16. Brexanolone. The FDA approved this drug for the treatment of postpartum depression. To follow DEA, this drug would be included as Schedule IV. Page 16, (c), (57).
17. Lemborexant. The FDA approved this drug for the treatment of insomnia in adult patients. To follow DEA, this drug would be included as Schedule IV. Page 16, (c), (58).
18. Solriamfetol. The FDA approved this drug to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. To follow DEA, this drug would be included as a Schedule IV. Page 16, (e), (14).
19. Lasmiditan. The FDA approved this drug for the acute treatment of migraine with or without aura in adults. To follow DEA, this drug would be included as Schedule V. Page 18, (e), (4).

20. Cenobamate. The FDA approved this drug for the treatment of partial-onset seizures in adult patients. To follow DEA, this drug would be included as Schedule V. Page 18, (e), (5).
21. A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols. This drug is currently listed as a Schedule V substance. Page 18, (f), (1). To follow DEA this drug is removed from the controlled substance list.
22. The following synthetic cannabinoids are schedule VI controlled substances. To follow DEA, controlled substance code numbers have been set forth opposite the following substances:
  - 5F-AKB-48, Page 21, (I), (v),
  - 5-Fluoro-AMB, Page 22, (K), (xv),
  - 5-Fluoro-ADB, Page 22, (K), (xvii),
  - MDMB-CHMICA, Page 22, (K), (xix),
  - FUB-AMB, Page 22, (K), (xx),
  - MDMB-FUBINACA, Page 22, (K), (xxi).
23. Two items marked for clean-up:
  - a. Page 22, (K), (xxiv)
  - b. Page 22, (K), (xxvii).
24. ADB-FUBINACA. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide. The DEA has scheduled this synthetic cannabinoid because it has no recognized medical use. This drug would be included as Schedule VI. Page 22, (K), (xxviii).
25. 4-Fluoro MDMB-BUTINACA. methyl (S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate. Felisia Lackey, Chief Forensic Chemist-Drug Section, Arkansas State Crime Laboratory, requested that this synthetic cannabinoid with no recognized medical use be included into Schedule VI. Page 23, (K), (xxix).

